Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target Lowered to $40.00 at HC Wainwright

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) had its price target cut by stock analysts at HC Wainwright from $50.00 to $40.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price objective indicates a potential upside of 466.57% from the company's current price. HC Wainwright also issued estimates for Corbus Pharmaceuticals' Q2 2025 earnings at ($1.54) EPS, Q3 2025 earnings at ($1.56) EPS, Q4 2025 earnings at ($1.58) EPS, FY2025 earnings at ($6.07) EPS, FY2026 earnings at ($6.27) EPS, FY2027 earnings at ($6.97) EPS, FY2028 earnings at ($5.09) EPS and FY2029 earnings at ($2.90) EPS.

A number of other brokerages have also recently commented on CRBP. StockNews.com raised Corbus Pharmaceuticals to a "sell" rating in a research note on Thursday, March 6th. William Blair began coverage on Corbus Pharmaceuticals in a research note on Friday, February 28th. They set an "outperform" rating on the stock. Wedbush reissued an "outperform" rating and set a $51.00 target price on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. Finally, Jefferies Financial Group reduced their target price on Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $50.88.

Corbus Pharmaceuticals Stock Performance

NASDAQ:CRBP traded up $0.61 during mid-day trading on Wednesday, reaching $7.06. The stock had a trading volume of 80,291 shares, compared to its average volume of 359,285. The firm has a 50 day moving average price of $6.33 and a two-hundred day moving average price of $10.77. The stock has a market capitalization of $86.36 million, a P/E ratio of -1.52 and a beta of 3.19. Corbus Pharmaceuticals has a one year low of $4.64 and a one year high of $61.90.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.13). Research analysts forecast that Corbus Pharmaceuticals will post -4.23 earnings per share for the current year.

Institutional Trading of Corbus Pharmaceuticals

Several institutional investors have recently made changes to their positions in CRBP. Velan Capital Investment Management LP grew its holdings in Corbus Pharmaceuticals by 13.4% during the 4th quarter. Velan Capital Investment Management LP now owns 56,700 shares of the biopharmaceutical company's stock valued at $669,000 after buying an additional 6,700 shares in the last quarter. Two Sigma Advisers LP purchased a new position in Corbus Pharmaceuticals during the 4th quarter valued at approximately $130,000. Two Sigma Investments LP grew its holdings in Corbus Pharmaceuticals by 212.3% during the 4th quarter. Two Sigma Investments LP now owns 134,175 shares of the biopharmaceutical company's stock valued at $1,583,000 after buying an additional 91,205 shares in the last quarter. Prosight Management LP lifted its stake in shares of Corbus Pharmaceuticals by 107.7% in the 4th quarter. Prosight Management LP now owns 270,000 shares of the biopharmaceutical company's stock valued at $3,186,000 after purchasing an additional 140,000 shares during the last quarter. Finally, Orbimed Advisors LLC lifted its stake in shares of Corbus Pharmaceuticals by 28.5% in the 4th quarter. Orbimed Advisors LLC now owns 1,172,287 shares of the biopharmaceutical company's stock valued at $13,833,000 after purchasing an additional 259,735 shares during the last quarter. Hedge funds and other institutional investors own 64.64% of the company's stock.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.